These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Smoking, cancer, and Parkinson's disease. Barbeau A; Roy M; Cloutier T Ann Neurol; 1986 Jul; 20(1):105-6. PubMed ID: 3740811 [No Abstract] [Full Text] [Related]
5. Debrisoquine oxidation in Parkinson's disease. Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454 [TBL] [Abstract][Full Text] [Related]
7. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465 [TBL] [Abstract][Full Text] [Related]
8. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021 [TBL] [Abstract][Full Text] [Related]
9. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R; Broly F; Destée A; Libersa C Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190 [No Abstract] [Full Text] [Related]
10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707 [TBL] [Abstract][Full Text] [Related]
11. Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease. Gudjonsson O; Sanz E; Alván G; Aquilonius SM; Reviriego J Br J Clin Pharmacol; 1990 Aug; 30(2):301-2. PubMed ID: 2206793 [No Abstract] [Full Text] [Related]
12. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development. Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140 [TBL] [Abstract][Full Text] [Related]
14. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Ohta S; Tachikawa O; Makino Y; Tasaki Y; Hirobe M Life Sci; 1990; 46(8):599-605. PubMed ID: 2308469 [TBL] [Abstract][Full Text] [Related]
15. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Brøsen K; Gram LF; Haghfelt T; Bertilsson L Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528 [TBL] [Abstract][Full Text] [Related]
16. Interethnic dissociation between debrisoquine and desipramine hydroxylation. Rudorfer MV; Lane EA; Potter WZ J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975 [TBL] [Abstract][Full Text] [Related]
17. Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564 [TBL] [Abstract][Full Text] [Related]
18. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Alvan G; von Bahr C; Seidemann P; Sjöqvist F Lancet; 1982 Feb; 1(8267):333. PubMed ID: 6120324 [No Abstract] [Full Text] [Related]